Holen Sie sich die Stockscreener-App
56.68
3.54%
1.94
Handel nachbörslich:
56.68
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$54.74
Offen:
$56.35
24-Stunden-Volumen:
2.99M
Relative Volume:
1.30
Marktkapitalisierung:
$8.87B
Einnahmen:
$1.22B
Nettoeinkommen (Verlust:
$81.07M
KGV:
110.25
EPS:
0.5141
Netto-Cashflow:
$223.02M
1W Leistung:
+5.92%
1M Leistung:
+6.68%
6M Leistung:
-5.44%
1J Leistung:
+13.82%
1-Tages-Spanne:
$54.51
$57.01
1-Wochen-Bereich:
$51.03
$57.01
52-Wochen-Spanne:
$46.05
$72.16
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
612-379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
56.68 | 8.56B | 1.22B | 81.07M | 223.02M | 0.5141 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-07-09 | Eingeleitet | TD Cowen | Buy |
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
Bio-Techne (TECH) executive nets shares from 794 RSU exercise - Stock Titan
Investors brace for Bio-Techne earnings amid muted outlook By Investing.com - Investing.com Canada
Bio-Techne sets 8 a.m. May 6 webcast for fiscal Q3 results - Stock Titan
Bio-Techne CEO Kim Kelderman to speak at BofA healthcare event - Stock Titan
Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference - ChartMill
Bio-Techne Corp (TECH) Stock Analysis: Evaluating a 31.36% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
MSN Money - MSN
Vanguard Group Inc. Sells 121,495 Shares of Bio-Techne Corp $TECH - MarketBeat
UBS Group AG Raises Position in Bio-Techne Corp $TECH - MarketBeat
Conestoga Capital Advisors LLC Boosts Stock Holdings in Bio-Techne Corp $TECH - MarketBeat
Comerica Bank Increases Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp. stock underperforms Thursday when compared to competitors - MSN
Understanding the Setup: (TECH) and Scalable Risk - Stock Traders Daily
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Vanguard (NASDAQ: TECH) holds 7.38% stake — 11.56M shares reported - Stock Titan
Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock? - Yahoo Finance
Bio-Techne (TECH) Expected to Announce Earnings on Wednesday - MarketBeat
Is There Now An Opportunity In Bio-Techne (TECH) After Recent Share Price Weakness - simplywall.st
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
M&T Bank Corp Buys 70,496 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp (TECH) Stock Analysis: Exploring a 33% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Impax Asset Management Group plc Invests $11.47 Million in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne (TECH) CEO nets shares after stock option exercise - Stock Titan
[Form 4] BIO-TECHNE Corp Insider Trading Activity - Stock Titan
Bio-Techne Corp. Stock Hits Day Low of $51.13 Amid Price Pressure - Markets Mojo
Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results - Investing News Network
What to expect from Bio-Techne's Q3 2026 earnings report - msn.com
Bio-Techne (NASDAQ:TECH) Stock Price Down 10.3%Time to Sell? - MarketBeat
Bio-Techne Corp. stock outperforms competitors despite losses on the day - MarketWatch
Bio-Techne Corp (TECH) Stock Analysis: Navigating a 22% Potential Upside Amidst Market Dynamics - DirectorsTalk Interviews
Bio-Techne Reorganizes Brand To Link Research Spatial And Diagnostics Workflows - Yahoo Finance
The Technical Signals Behind (TECH) That Institutions Follow - Stock Traders Daily
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know - Yahoo Finance
Arvin Capital Management LP's Bio-Techne Corp(TECH) Holding History - GuruFocus
What to Expect From Bio-Techne's Q3 2026 Earnings Report - Barchart.com
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity - Investing News Network
Bio-Techne (TECH) CEO exercises 36,500 options and uses 32,088 shares for taxes - Stock Titan
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):